Amyotrophic Lateral Sclerosis (ALS) Market Report

Global Amyotrophic Lateral Sclerosis (ALS) Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 24, 2022
  • PAGES：163
  • REPORT CODE：GMM771575
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Amyotrophic Lateral Sclerosis (ALS) market report explains the definition, types, applications, major countries, and major players of the Amyotrophic Lateral Sclerosis (ALS) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Covis Pharma

    • Sun Pharma

    • Apotex

    • Glemark Generics

    • Sanofi

    • Mylan Pharma

    • Mitsubishi Tanabe Pharma

    • Lunan Pharma

    By Type:

    • Riluzole

    • Edaravone (Radicava)

    • Other

    By End-User:

    • Hospital

    • Drugs Store

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Amyotrophic Lateral Sclerosis (ALS) Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Amyotrophic Lateral Sclerosis (ALS) Outlook to 2028- Original Forecasts

    • 2.2 Amyotrophic Lateral Sclerosis (ALS) Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Amyotrophic Lateral Sclerosis (ALS) Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Amyotrophic Lateral Sclerosis (ALS) Market- Recent Developments

    • 6.1 Amyotrophic Lateral Sclerosis (ALS) Market News and Developments

    • 6.2 Amyotrophic Lateral Sclerosis (ALS) Market Deals Landscape

    7 Amyotrophic Lateral Sclerosis (ALS) Raw Materials and Cost Structure Analysis

    • 7.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials

    • 7.2 Amyotrophic Lateral Sclerosis (ALS) Price Trend of Key Raw Materials

    • 7.3 Amyotrophic Lateral Sclerosis (ALS) Key Suppliers of Raw Materials

    • 7.4 Amyotrophic Lateral Sclerosis (ALS) Market Concentration Rate of Raw Materials

    • 7.5 Amyotrophic Lateral Sclerosis (ALS) Cost Structure Analysis

      • 7.5.1 Amyotrophic Lateral Sclerosis (ALS) Raw Materials Analysis

      • 7.5.2 Amyotrophic Lateral Sclerosis (ALS) Labor Cost Analysis

      • 7.5.3 Amyotrophic Lateral Sclerosis (ALS) Manufacturing Expenses Analysis

    8 Global Amyotrophic Lateral Sclerosis (ALS) Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Amyotrophic Lateral Sclerosis (ALS) Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Amyotrophic Lateral Sclerosis (ALS) Export by Region (Top 10 Countries) (2017-2028)

    9 Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook by Types and Applications to 2022

    • 9.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Riluzole Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Drugs Store Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Outlook till 2022

    • 10.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.2.2 Canada Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.2.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.2 UK Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.3 Spain Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.4 Belgium Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.5 France Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.7 Denmark Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.8 Finland Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.9 Norway Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.10 Sweden Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.11 Poland Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.12 Russia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.3.13 Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.2 Japan Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.3 India Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.5 Pakistan Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.6 Bangladesh Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.7 Indonesia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.8 Thailand Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.9 Singapore Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.10 Malaysia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.11 Philippines Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.4.12 Vietnam Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.3 Chile Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.4 Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.5 Venezuela Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.6 Peru Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.7 Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.5.8 Ecuador Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.6.2 Kuwait Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.6.3 Oman Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.6.4 Qatar Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.7.2 South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.7.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.7.4 Algeria Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

      • 10.8.2 New Zealand Amyotrophic Lateral Sclerosis (ALS) Consumption (2017-2022)

    11 Global Amyotrophic Lateral Sclerosis (ALS) Competitive Analysis

    • 11.1 Covis Pharma

      • 11.1.1 Covis Pharma Company Details

      • 11.1.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.1.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Sun Pharma

      • 11.2.1 Sun Pharma Company Details

      • 11.2.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.2.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Apotex

      • 11.3.1 Apotex Company Details

      • 11.3.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.3.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Glemark Generics

      • 11.4.1 Glemark Generics Company Details

      • 11.4.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.4.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Sanofi

      • 11.5.1 Sanofi Company Details

      • 11.5.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.5.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Mylan Pharma

      • 11.6.1 Mylan Pharma Company Details

      • 11.6.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.6.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Mitsubishi Tanabe Pharma

      • 11.7.1 Mitsubishi Tanabe Pharma Company Details

      • 11.7.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.7.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Lunan Pharma

      • 11.8.1 Lunan Pharma Company Details

      • 11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

      • 11.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    12 Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook by Types and Applications to 2028

    • 12.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Drugs Store Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Outlook to 2028

    • 13.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.2.2 Canada Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.2 UK Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.3 Spain Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.5 France Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.8 Finland Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.9 Norway Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.11 Poland Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.12 Russia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.2 Japan Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.3 India Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.3 Chile Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.6 Peru Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.6.3 Oman Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Amyotrophic Lateral Sclerosis (ALS)

    • Figure of Amyotrophic Lateral Sclerosis (ALS) Picture

    • Table Global Amyotrophic Lateral Sclerosis (ALS) Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Amyotrophic Lateral Sclerosis (ALS) Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Riluzole Consumption and Growth Rate (2017-2022)

    • Figure Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Drugs Store Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Table North America Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure United States Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Canada Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table Europe Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure Germany Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure UK Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Spain Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Belgium Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure France Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Italy Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Denmark Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Finland Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Norway Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Sweden Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Poland Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Russia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table APAC Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure China Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Japan Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure India Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Thailand Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Singapore Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Philippines Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table South America Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Colombia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Chile Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Peru Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table GCC Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure Bahrain Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Oman Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Qatar Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table Africa Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure Nigeria Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure Algeria Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table Oceania Amyotrophic Lateral Sclerosis (ALS) Consumption by Country (2017-2022)

    • Figure Australia Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Amyotrophic Lateral Sclerosis (ALS) Consumption and Growth Rate (2017-2022)

    • Table Covis Pharma Company Details

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Sun Pharma Company Details

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Apotex Company Details

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Glemark Generics Company Details

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Mylan Pharma Company Details

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Mitsubishi Tanabe Pharma Company Details

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Table Lunan Pharma Company Details

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Main Business and Markets Served

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio

    • Figure Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Drugs Store Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Table North America Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure United States Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure Germany Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure China Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Country (2022-2028)

    • Figure Australia Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US